問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Tri-Service General Hospital

Division of Thoracic Medicine

List

81Cases

2017-02-28 - 2020-02-11

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

2019-06-01 - 2021-09-28

Phase II

A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    M7824

Participate Sites
5Sites

Recruiting5Sites

2018-12-15 - 2022-09-27

Phase II

An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    M7824

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

沈佳儀
Taipei Veterans General Hospital

Division of Thoracic Medicine

2013-12-23 - 2021-08-12

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2018-06-01 - 2022-09-30

Phase III

RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy

  • Condition/Disease

    Small cell lung cancer

  • Test Drug

    ONIVYDE

Participate Sites
5Sites

Recruiting5Sites

劉劍英
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2009-09-01 - 2013-09-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2011-04-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2015-09-30 - 2018-09-30

Phase II

A multi-center, randomized, double-blind, placebo controlled study to investigate the efficacy and safety of 52 weeks treatment with QGE031 s.c. in asthma patients not adequately controlled by medium- or high-dose ICS plus LABA with or without OCS

  • Condition/Disease

    Asthma

  • Test Drug

    QGE031

Participate Sites
3Sites

Terminated3Sites

2010-09-01 - 2012-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2012-06-15 - 2013-02-28

Phase III

A 12-week treatment, randomized, blinded, double-dummy, parallel-group study to assess the efficacy, safety, and tolerability of NVA237 (50 μg o.d.) compared to tiotropium (18 μg o.d.) in patients with chronic obstructive pulmonary disease (COPD)

  • Condition/Disease

    COPD

  • Test Drug

    NVA237

Participate Sites
7Sites

Terminated7Sites

1 4 5 6 7 8 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB